

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if known	
				Application Number	10/588,166
				Filing Date	February 16, 2005
				First Named Inventor	Pedro Cuevas Sanchez, et al.
				Art Unit	1628
				Examiner Name	Anna Pagonakis
Sheet	1	of	1	Attorney Docket Number	544940-202.1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Classification
		Number-Kind Code ² (if known)			
	AA				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-YYYY	Country	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	AB					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AC	English Translation of Acnisdin and Acnisdin Retinoico entries in Catalogo de especialidades farmaceuticas 1991, Consejo General de Colegios Oficiales De Farmaceuticos, Madrid, Spain, p. 674	
	AD	Travis L et al. Drugs of Today 38:847-865 (2002)	
	AE	Jegasothy BV Arch Dermatol 128:781-785 (1992)	
	AF	Banarroch IS et al Ophthalmic Res 17:131-138 (1985)	
	AG	Lozano RM J Mol Biol 281:899-9115 (1998)	
	AH	Trozak. Cutis. Chatham 64:315-318 (1999)	
	AI	Wollina V et al. Clin Rheumatol 20:406-410 (2001)	
	AJ	Niwa Y et al. B J Dermatol 149:960-967 (2003)	
	AK	Michal M et al. Thromb Res 51:593-605 (1988)	
	AL	Benakis A et al. Therapie 29:211-219 (1974)	
	AM	Suscheck C et al. Bt J Pharmacol 122:1502-1508 (1997)	
	AN	Angulo J et al. Br J Pharmacol 139:854-862 (2003)	
	AO	Brunet J et al Fundam Clin Pharmacol 12:205-212 (1998)	
	AP	Kocak M et al Int J Dermatol 42:789-793 (2003)	
	AQ	Karasek MA Cutis 64:319-322 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.